News | November 25, 2023
DxVx plans to make a license-in agreement of OVM-200
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Azelis will be the exclusive distributor for inulin, oligofructose, scFOS, texturized wheat proteins, faba beans, Beta-glucans, meatless solution
Distributes Ayushman cards to several beneficiaries
Evinova will operate as a separate health-tech business within AstraZeneca
OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Collaboration enables Brenntag to serve pharma customers in EMEA with chromatography silica gels
Subscribe To Our Newsletter & Stay Updated
